Among them, in the studies of “Kim2018 PD1 Gastric” (AUC=0.85) and “Gide2019 PD1 Melanoma” (AUC=0.83), the CXCL13 predictive power of response outcome was better than other published biomarkers. Here, CXCL13 is linked to melanoma.